Brief: ABVC Biopharma Provides ADHD Phase II Part 2 Clinical Study Update

ABVC Biopharma

23/09/2022 13:46

Sept 23 (Reuters) - ABVC Biopharma Inc  ABVC.O :
    * ABVC BIOPHARMA PROVIDES ADHD PHASE II PART 2 CLINICAL
STUDY
UPDATE AND ANNOUNCES UCSF INSTITUTIONAL REVIEW BOARD APPROVAL
    * ABVC BIOPHARMA - SINCE RESULTS OF 1ST SUBJECT TREATED IN
TAIWAN
REPORTED ON MAY 10, 30 SUBJECTS ENROLLED IN STUDY FROM TOTAL OF
43 SUBJECTS SCREENED
    * ABVC BIOPHARMA INC - 18 OF ENROLLED PARTICIPANTS HAVE
ALREADY
COMPLETED 8-WEEK TREATMENT IN ACCORDANCE WITH STUDY DESIGN

Source text for Eikon:  ID:nGNXbnqdcn 
Further company coverage:  ABVC.O 
 ((Reuters.Briefs@thomsonreuters.com;))